Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Olabisi Osunmakinde"'
Autor:
Olabisi Osunmakinde, Brian Ruffell
Publikováno v:
Cancer Research. 83:2881-2881
Background: Androgens stimulate androgen receptor (AR) signaling, driving prostate cancer (PC) cell proliferation and progression. Androgen deprivation therapy (ADT) effectively treats primary disease, but 20-30% of patients relapse after ~5 years, r
Autor:
Kay Hänggi, Aysenur Keske, Alycia Gardner, Jie Li, Olabisi Osunmakinde, Daiana Celias, Amer Beg, Brian Ruffell
Publikováno v:
Cancer Research. 83:655-655
Programmed cell death (PCD) was originally limited to apoptosis, but now includes pyroptosis, ferroptosis, necroptosis, and paraptosis. Necroptosis has attracted particular interest as an approach for immunotherapy as activation of the RIPK1/RIPK3 ne
Autor:
Olabisi Osunmakinde, Daiana Pamela Celias, Kay Hänggi, Alexis Onimus, Eslam Mohamed, Bruna Batista-Bittencourt, Xiaoqing Yu, Alycia Gardner, Álvaro de Mingo Pulido, Vincent C. Luca, Hatem Soliman, Tsuneyasu Kaisho, Kristen McEachern, Jie Li, Reymi Peña, Jimena Trillo-Tinoco, Brian Ruffell, Paulo C. Rodriguez, Johanna Kaufmann
Publikováno v:
de Mingo Pulido, Á, Hänggi, K, Celias, D P, Gardner, A, Li, J, Batista-Bittencourt, B, Mohamed, E, Trillo-Tinoco, J, Osunmakinde, O, Peña, R, Onimus, A, Kaisho, T, Kaufmann, J, McEachern, K, Soliman, H, Luca, V C, Rodriguez, P C, Yu, X & Ruffell, B 2021, ' The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake ', Immunity, vol. 54, no. 6, pp. 1154-1167 . https://doi.org/10.1016/j.immuni.2021.04.019
Immunity
Immunity
Blockade of the inhibitory receptor TIM-3 shows efficacy in cancer immunotherapy clinical trials. TIM-3 inhibits production of the chemokine CXCL9 by XCR1+ classical dendritic cells (cDC1), thereby limiting antitumor immunity in mammary carcinomas. W